T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer
PDF | HTML | How to cite
Metrics: PDF 1470 views | HTML 1679 views | ?
Jacky Yu-Chung Li1, James Chung-Man Ho2 and Kam-Hung Wong1
1Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR
2Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR
Jacky Yu-Chung Li, email: [email protected]
Keywords: adenocarcinoma; lung carcinoma; osimertinib; ddPCR; mutant copy number
Received: December 18, 2017 Accepted: March 24, 2018 Published: June 15, 2018
Osimertinib prolongs progression-free survival (PFS) in patients with metastatic, epidermal growth factor receptor (EGFR) T790M-mutated, non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitor (TKI) therapy. We investigated the utility of T790M mutant copy number quantification in a plasma cell-free DNA (cfDNA) assay for predicting clinical outcomes of osimertinib treatment. We retrospectively examined 161 patients who underwent plasma EGFR testing using a digital droplet polymerase chain reaction (ddPCR) technique after EGFR-TKI failure. Of the 74 (46%) patients with detectable T790M mutations in plasma, 55 received osimertinib treatment. Patients who achieved partial response had a higher plasma mutant copy levels than those with progressive disease. Patients who achieved stable disease also tended to have higher plasma mutant copy levels than those with progressive disease. High mutant copy number (≥ 105 per mL of plasma) was associated with shorter PFS (median: 5.5 months vs. not reached) and overall survival (median: 9.1 months vs. NR). Quantitative measurements of T790M mutant copy number in plasma cfDNA by ddPCR thus predicted treatment response and survival outcomes after osimertinib in NSCLC patients resistant to EGFR TKI.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.